|3.56|| +0.01 / +0.28%|
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company with a focus on oncology and acute radiation syndrome drug development. It is engaged in the research, development and commercialization of products that have the potential to treat cancer, reduce death from total body irradiation and counteract the toxic effects of radio and chemotherapies for oncology patients. The company has designed two oppositely-directed general therapeutic concepts: temporary and reversible suppression of apoptosis in normal cells to protect healthy tissues from stress-induced damage using compounds categorized as Protectans; and reactivation of apoptosis in tumor cells to eliminate cancer using compounds categorized as Curaxins. The company was founded by Andrei V. Gudkov on June 5, 2003 and is headquartered in Buffalo, NY.
|Yakov Kogan||Chief Executive Officer & Director|
|Leah Brownlee||Secretary, VP-Compliance & Operations|
|C. Neil Lyons||CFO, Head-Investor & Public Relations|
|Andrei V. Gudkov||Director & Chief Scientific Officer|
|Michael R. Kurman||Chief Medical Officer|